Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma A/S (ASND)
:ASND
ASND Stock Chart & Stats
Day’s Range― - ―
52-Week Range$111.09 - $186.89
Previous CloseN/A
Volume129.18K
Average Volume (3M)423.18K
Market Cap
$11.27B
Enterprise Value$9.71B
Total Cash (Recent Filing)$517.92M
Total Debt (Recent Filing)$847.27M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Nov 13, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding60,970,566
10 Day Avg. Volume446,358
30 Day Avg. Volume423,177
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue31.24
Enterprise Value/Gross Profit36.25
Enterprise Value/Ebitda-55.75
Forecast
1Y Price Target
$231.86Price Target Upside24.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessASND recently reported positive Phase 2 COACH data evaluating Skytrofa as a combination therapy in children with achondroplasia, and will initiate a Phase 3 study.
Regulatory ApprovalThe FDA approved Skytrofa in adults with growth hormone deficiency, which positively impacts the company's ability to expand Skytrofa's label and establish their commercial infrastructure.
Bears Say
Market CompetitionVoxzogo from BioMarin, a competitor, already has low-teen percent market penetration, which could pose competition for market share.
Market FragmentationSkytrofa sales in children with GHD haven't been strong, which isn't surprising given the GHD market is established and fragmented.
Ascendis Pharma News
ASND FAQ
What was Ascendis Pharma A/S’s price range in the past 12 months?
Ascendis Pharma A/S lowest stock price was $111.09 and its highest was $186.89 in the past 12 months.
What is Ascendis Pharma A/S’s market cap?
Ascendis Pharma A/S’s market cap is $11.27B.
When is Ascendis Pharma A/S’s upcoming earnings report date?
Ascendis Pharma A/S’s upcoming earnings report date is Nov 13, 2025 which is in 98 days.
How were Ascendis Pharma A/S’s earnings last quarter?
Ascendis Pharma A/S released its earnings results on Aug 07, 2025. The company reported -$0.956 earnings per share for the quarter, beating the consensus estimate of -$1.499 by $0.543.
Is Ascendis Pharma A/S overvalued?
According to Wall Street analysts Ascendis Pharma A/S’s price is currently Undervalued.
Does Ascendis Pharma A/S pay dividends?
Ascendis Pharma A/S does not currently pay dividends.
What is Ascendis Pharma A/S’s EPS estimate?
Ascendis Pharma A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascendis Pharma A/S have?
Ascendis Pharma A/S has 60,970,566 shares outstanding.
What happened to Ascendis Pharma A/S’s price movement after its last earnings report?
Ascendis Pharma A/S reported an EPS of -$0.956 in its last earnings report, beating expectations of -$1.499. Following the earnings report the stock price went up 2.741%.
Which hedge fund is a major shareholder of Ascendis Pharma A/S?
Currently, no hedge funds are holding shares in ASND
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$231.86 (24.26% Upside)
$231.86 (24.26% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 189.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 13.3%
Last 30 Days ▲ 13.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.28%
12-Months-Change
Fundamentals
Return on Equity
357.68%
Trailing 12-Months
Asset Growth
32.29%
Trailing 12-Months
Company Description
Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is a biopharmaceutical company focused on improving patient outcomes through the development of innovative therapies. The company operates primarily in the healthcare sector, specializing in endocrinology and oncology. Its core products include TransCon growth hormone for pediatric growth hormone deficiency, and the company is also exploring treatments in other therapeutic areas using its proprietary TransCon technology platform, which allows for sustained release of drugs to improve efficacy and patient experience.
ASND Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights Ascendis Pharma's strong launch and revenue growth for YORVIPATH, alongside significant advances in their product pipeline. However, this success is tempered by increased operating expenses and ongoing challenges in securing insurance reimbursements. Overall, the sentiment is balanced with significant achievements and operational challenges.View all ASND earnings summariesASND Stock 12 Month Forecast
Average Price Target
$231.86
▲(24.26% Upside)
Technical Analysis
Ownership Overview
―
Insiders
31.93% Mutual Funds
0.21% Other Institutional Investors
66.44% Public Companies and
Individual Investors